Ra­dius Phar­ma sells off part of its roy­al­ties, mile­stones in breast can­cer drug Orser­du

Ra­dius Phar­ma­ceu­ti­cals is pulling in an up­front pay­ment of $130 mil­lion from DRI Health­care as part of a roy­al­ty pur­chase agree­ment for its breast can­cer drug elaces­trant, the Boston-based biotech an­nounced Mon­day.

Ra­dius Phar­ma­ceu­ti­cals, a sub­sidiary of Ra­dius Health, could al­so re­ceive an­oth­er $10 mil­lion from DRI if “cer­tain events” hap­pen. Ra­dius will keep more than $200 mil­lion in po­ten­tial com­mer­cial mile­stones from the Menar­i­ni Group, which snagged glob­al com­mer­cial and de­vel­op­ment rights to elaces­trant for on­ly $30 mil­lion in Ju­ly 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER